WRBY Warby Parker Inc.
Ophthalmic Goods · NYSE · SEC CIK 1504776 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.9%
TTM net income YoY942.0%
TTM EPS YoY216,172,782,113,783,936.0%
Revenue 3-yr CAGR12.6%
Net income 3-yr CAGR—
Margins
Gross margin54.7%
Operating margin0.2%
Net margin0.8%
FCF margin2.3%
EBITDA margin6.1%
Returns
ROE1.9%
ROA1.0%
ROIC (approx.)1.1%
Asset turnover1.25x
Leverage & solvency
Liabilities / assets49.1%
Debt / equity0.00x
Current ratio2.26x
Interest coverage—
Cash quality & payout
Operating cash flow / net income13.67x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue8.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $871.90M | $771.32M | $669.76M | $598.11M | $540.80M |
| Cost of revenue | $401.33M | $344.48M | $304.54M | $257.05M | $223.05M |
| Gross profit | $470.58M | $426.83M | $365.22M | $341.06M | $317.75M |
| SG&A expense | $475.92M | $456.95M | $437.22M | $452.26M | $461.41M |
| Operating income | -$5.34M | -$30.11M | -$72.00M | -$111.20M | -$143.66M |
| Pretax income | $3.04M | -$19.52M | -$62.76M | -$109.90M | -$144.01M |
| Income tax | $1.40M | $875,000 | $433,000 | $497,000 | $263,000 |
| Net income | $1.64M | -$20.39M | -$63.20M | -$110.39M | -$144.27M |
| EBITDA | $44.94M | $15.75M | -$33.44M | -$79.34M | -$122.11M |
| EPS (basic) | 0.01 | -0.17 | -0.54 | -0.96 | -2.21 |
| EPS (diluted) | 0.01 | -0.17 | -0.54 | -0.96 | -2.21 |
| Weighted avg. shares (diluted) | 125.10M | 120.39M | 117.39M | 114.94M | 71.25M |
| Balance sheet | |||||
| Cash & equivalents | $286.36M | $254.16M | $216.89M | $208.59M | $256.42M |
| Receivables | $3.29M | $1.95M | $1.78M | $1.44M | $992,000 |
| Inventory | $44.51M | $52.34M | $62.23M | $68.85M | $57.09M |
| Current assets | $352.44M | $326.05M | $298.62M | $294.57M | $327.98M |
| PP&E, net | $187.45M | $170.46M | $152.33M | $138.63M | $112.19M |
| Total assets | $720.92M | $676.49M | $580.31M | $568.71M | $440.65M |
| Current liabilities | $150.13M | $130.35M | $127.09M | $129.56M | $118.10M |
| Total liabilities | $353.19M | $336.42M | $278.52M | $282.06M | $154.65M |
| Shareholders' equity | $367.73M | $340.07M | $301.79M | $286.65M | $286.00M |
| Cash flow statement | |||||
| Operating cash flow | $110.78M | $98.74M | $60.99M | $10.37M | -$31.99M |
| Capital expenditure | $67.05M | $64.03M | $53.67M | $60.18M | $48.51M |
| Free cash flow | $43.74M | $34.71M | $7.32M | -$49.81M | -$80.51M |
| Investing cash flow | -$67.05M | -$66.03M | -$54.67M | -$60.18M | -$48.51M |
| Financing cash flow | -$12.00M | $4.96M | $2.87M | $3.29M | $23.00M |
| Depreciation & amortization | $50.28M | $45.87M | $38.55M | $31.86M | $21.55M |
| Stock-based compensation | $34.54M | $47.29M | $70.51M | $98.03M | $107.15M |
| Share buybacks | — | — | $0 | $0 | $8.09M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.